Evaluation of the Effects of Baricitinib in Acute Respiratory Distress Syndrome (ARDS) Patients

Evaluation of the Effects of Baricitinib in Acute Respiratory Distress Syndrome (ARDS) Patients: A Randomized Clinical Trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20231017059748N3

Enrollment

Registered

2023-12-14

Start date

2023-12-06

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute respiratory distress syndrome. Severe acute respiratory syndrome [SARS], unspecified

Interventions

Intervention 1: Intervention group: Baricitinib of Nano Daro Alvand Company will be prescribed at a dose of 4 mg daily orally for 14 days or until discharge from the hospital. Patients whose glomerula

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Adults with mild to moderate Acute Respiratory Distress Syndrome (ARDS) who require oxygen therapy (PaO2/FiO2 < 300 mmHg) Patients who are capable of long-term supine position

Exclusion criteria

Exclusion criteria: Pregnancy Age below 18 and above 80 years concomitant diseases (infection/suppression of immune system, human immunodeficiency virus, liver, kidney and/acquired immunodeficiency syndrome)

Design outcomes

Primary

Measure	Time frame
High-flow nasal oxygen therapy and noninvasive ventilation. Timepoint: Length of hospital stay. Method of measurement: observation.;Invasive mechanical ventilation. Timepoint: Length of hospital stay. Method of measurement: observation.	—

Secondary

Measure	Time frame
O2 saturation. Timepoint: Twice a day (morning and evening) and while receiving non-invasive ventilation until the patient is hospitalized in the intensive care unit. Method of measurement: Pulse oximeter.;Duration of stay in intensive care unit. Timepoint: From the time of admission to the intensive care unit until the time of discharge or death. Method of measurement: Observation.;The number of days without a ventilator. Timepoint: Length of hospital stay. Method of measurement: Observation.;Duration of recovery. Timepoint: Length of hospital stay. Method of measurement: Observation.;Paient outcom. Timepoint: Length of hospital stay. Method of measurement: Observation.	—

Measure

Time frame

O2 saturation. Timepoint: Twice a day (morning and evening) and while receiving non-invasive ventilation until the patient is hospitalized in the intensive care unit. Method of measurement: Pulse oximeter.;Duration of stay in intensive care unit. Timepoint: From the time of admission to the intensive care unit until the time of discharge or death. Method of measurement: Observation.;The number of days without a ventilator. Timepoint: Length of hospital stay. Method of measurement: Observation.;Duration of recovery. Timepoint: Length of hospital stay. Method of measurement: Observation.;Paient outcom. Timepoint: Length of hospital stay. Method of measurement: Observation.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHadi Hamishehkar

Tabriz University of Medical Sciences

hamishehkar@gmail.com+98 41 3334 7054

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026